A subcutaneous formulation of rituximab has been shown to have a similar efficacy and safety profile as intravenous rituximab in the treatment of follicular lymphoma. The international, phase 3 SABRINA study of more than 400 patients found 1400mg subcutaneous or 375mg/m2 intravenous rituximab in addition to chemotherapy achieved similar overall response rates at the end ...
Subcut rituximab matches IV for follicular lymphoma
By Mardi Chapman
25 May 2017